Biocon’s research arm Syngene lists at 295 rupees a share which is at a healthy 18% premium to its issue price. The management told ET NOW that the IPO proceeds will be used to fund Biocon's R&D needs. Listen in to Biocon CMD – Kiran Mazumdar Shaw and Syngene International’s Director – Peter Bains.
